Quidel Receives Emergency Use Authorization for Moderately Complex Solana® SARS Molecular Test for COVID-19 Diagnosis

SAN DIEGO–(BUSINESS WIRE)–Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a leading provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) to market its Solana® SARS-CoV-2 Assay, an isothermal Reverse Transcriptase – Helicase-Dependent Amplification (RT-HDA) assay intended for the qualitative detection of nucleic acid f